Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

PAH implant study halted, shifts to patient support

NCT ID NCT01321073

First seen Jan 30, 2026 · Last updated Jun 18, 2026 · Updated 22 times

Summary

This study looked at the safety of a special catheter and pump system implanted in the body to deliver a drug called Remodulin for people with pulmonary arterial hypertension (high blood pressure in the lungs). The study enrolled 64 participants. The company stopped developing the system, so the study now focuses on supporting the roughly 30 people who still have the implant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • AdventHealth Orlando

    Orlando, Florida, 32803, United States

  • Aurora St. Lukes Medical Center

    Milwaukee, Wisconsin, 53234, United States

  • Brigham & Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

  • University of Chicago Medical Center

    Chicago, Illinois, 60637, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390-7208, United States

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California, 90073, United States

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.